drugset
drugset / Trial / NCT04642079

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

NCT04642079 ↗

Phase 3 Completed 839 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age

Timeline

Start
2020-12-04
Primary completion
2022-04-06
Completion
2022-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 20vPnC Vaccine — —

Indications

pneumococcal infection